Table 2.
The clinicopathological characteristics of participants.
| Age (mean ± SD) | 60 ± 2.59 |
| Gender | Female: 7 (46.66) Male: 8 (53.33) |
| Tumor type | HCC: 15 (100%) |
| TNM∗ Primary tumor Regional lymph nodes Distant metastasis |
T2: 4 (26.66%); T3: 7 (46.66%); T4: 4(26.66%) 0 (0.0%) 0 (0.0%) |
| Stage | II: 4 (26.66%) IIIA: 7 (46.66%) IIIB: 4 (26.66%) |
| Tumor size | <2 : 6 (40%) ≤2–5 ≤: 7 (46.66%) 5 >: 2 (13.34%) |
| Hepatitis B | 2 (13.34%) |
| Smoking history | 6 (40%) |
| Alcohol consumption | 44(26.66%) |
| WBC | 9766 ± 1240 |
| Hb (g/dl) | 11.67 ± 1.54 |
| Hct (%) | 39.45 ± 3.18 |
| FBS (mg/dl) | 96.11 ± 7.9 |
| Creatinine (mg/dl) | 0.96 ± 0.16 |
| BUN (mg/dl) | 15.56 ± 3.19 |
| Urea (mg/dl) | 9.67 ± 2.54 |
| AST (U/L) | 36.43 ± 3.12 |
| ALT(U/L) | 34.8 ± 4.39 |
| Albumin (g/dl) | 3.86 ± 0.81 |
| Total bilirubin (mg/dl) | 1.06 ± 0.4 |
| PT (seconds) | 13.5 ± 1.67 |
| PTT (seconds) | 34.1 ± 3.89 |
∗TNM staging based on AJCC 8th edition. HCC: hepatocellular carcinoma; Hb: hemoglobin; Hct; hematocrit; FBS: fasting blood sugar; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine transaminase; PT: prothrombin time; PTT: partial thromboplastin time.